Case Reports in Infectious Diseases

Case Reports in Infectious Diseases / 2014 / Article

Case Report | Open Access

Volume 2014 |Article ID 270521 |

Turkan Aydin Teke, Fatma Nur Oz, Ozge Metin, Gulsum Iclal Bayhan, Zeynep Gökce Gayretli Aydin, Melek Oguz, Gonul Tanir, "Chryseobacterium indologenes Septicemia in an Infant", Case Reports in Infectious Diseases, vol. 2014, Article ID 270521, 4 pages, 2014.

Chryseobacterium indologenes Septicemia in an Infant

Academic Editor: Raul Colodner
Received20 Feb 2014
Accepted30 Jun 2014
Published10 Jul 2014


Chryseobacterium indologenes is a rare cause of infection in children. The organism causes infections mostly in hospitalised patients with severe underlying diseases. The choice of an effective drug for the treatment of infections due to C. indologenes is difficult as the organism has a limited spectrum of antimicrobial sensitivity. We present a case of nosocomial septicemia caused by C. indologenes in an infant with congenital heart disease who was successfully treated with trimethoprim sulfamethoxazole and also reviewed fourteen additional cases of C. indologenes infections reported in the English literature in this report.

1. Introduction

Chryseobacterium indologenes is nonmotile, catalase-positive, oxidase-positive, indole-positive, non-glucose-fermenting Gram-negative bacilli. It is not a component of human flora although it is widely distributed in nature. C. indologenes is a rare organism that has been reported to cause infections mostly in hospitalised patients with severe underlying diseases [1, 2]. The appropriate antibiotic choice is challenging as the organism shows resistance to multiple antibiotics. This report describes a case of C. indologenes nosocomial septicemia in an infant with congenital heart disease and reviews previously reported infections by C. indologenes in pediatric age group.

2. Case Report

A three-month-old female infant born at term by vaginal delivery presented to our hospital with cough and irritability. Atrioventricular septal defect was diagnosed when she was 15-day-old and she was on followup by cardiology clinic. On admission she had tachypnea and cardiac murmur on auscultation. All the other physical examinations of her were unremarkable. A complete blood count showed a white blood cell (WBC) count of 11.000/mm³ with 60% lymphocytes and C-reactive protein (CRP) level was 1 mg/L (range, 0–8 mg/L). Serum biochemical investigations were in normal range. Chest X-ray showed hyperinflation and peribronchiolar wall thickening. She was hospitalized for acute community acquired pneumonia and ampicillin sulbaktam plus clarithromycin was initiated. Respiratory virus multiplex polymerase chain reaction (PCR) obtained at admission revealed respiratory syncytial virus. Blood culture was performed since her clinical condition deteriorated and fever occurred on day 6. Candida albicans was isolated on blood culture and she was treated for nosocomial candidemia with caspofungin for 21 days, serial blood cultures were negative, and she was discharged in a good clinical condition. Four days after discharge, she was rehospitalized for the diagnosis of nosocomial pneumonia and empirically treated with meropenem and caspofungin intravenously. Blood and urine cultures showed no growth. During the hospitalization, fever up to 39°C occurred. She had a central venous catheter and her remaining physical examination was unremarkable. Laboratory investigations were as follows: hemoglobin 9.5 mg/dL, WBC 22.200/mm3 with 70% neutrophil, platelets 516.000/mm3, and CRP 21.1 mg/L. Chest X-ray showed no new infiltration and also abdominal ultrasonography and echocardiography did not show any infectious focus. Central venous catheter was removed because of obstruction. Specimen from peripheral blood culture yielded yellow colonies on blood agar (Figure 1). C. indologenes was identified by conventional methods and VITEK 2 ID-AST (bioMérieux, France) automatized system. Antimicrobial susceptibility testing of the organism revealed resistance to amikacin, gentamicin, ceftazidime, cefepime, piperacillin tazobactam, cefoperazone sulbactam, imipenem, meropenem, colistin, tetracycline, and ciprofloxacin and was susceptible to only trimethoprim sulfamethoxazole (TMP-SMX). TMP-SMX (20 mg/kg/day, intravenously) was initiated. Her fever resolved and blood culture became negative after 48 hours of the treatment. The antibiotic treatment was given for a course of 21 days. After discharge she was operated on in another hospital. She has been on followup in a good clinical condition for seven months.

3. Discussion

The genus Chryseobacterium (previously Flavobacterium) belongs to the family Flavobacteriaceae that are ubiquitous in nature and are inhabitants of soil and water and can be recovered from a variety of foods. They can be found in municipal water supplies despite adequate chlorination and can be recovered from the hospital environment [3]. Contamination of the medical devices containing water (respirators, intubation tubes, humidifiers, etc.) in hospital settings may lead to serious infections. C. indologenes colonies usually form a dark-yellow pigment in culture as a result of the production of the pigment flexirubin.

C. indologenes is a rare cause of human disease. C. indologenes was first isolated from a clinical specimen in 1993 from the tracheal aspirate of a patient with ventilator-associated pneumonia [4]. Chryseobacteria represent only 0.27% (50 of 18,569) of the processed nonfermentative Gram-negative bacilli and 0.03% (50 of 155,811) of all bacterial isolates collected by the SENTRY Surveillance Program during the 5-year period 1997 to 2001 [5]. C. indologenes infections have been shown as a cause for a variety of invasive infections especially in patients with risk factors, such as intravascular catheter-related bacteremia, bacteremia associated with malignancy and neutropenia, nosocomial pneumonia, cellulitis, meningitis, peritonitis, and surgical wound infections [2, 611]. A total of 14 cases of C. indologenes infections in pediatric age group were found in English literature. The diagnoses of the reported cases were bacteremia (six cases), meningitis (five cases), ventilator-associated pneumonia (two cases), and lumboperitoneal shunt infection (one case). Ten of 14 patients had medical devices, 12 of 14 patients had comorbidity, and 12 of 14 patients were ≤2 years old. The summary of cases is presented in Table 1.

Patient no.Reference/yearAge/sexComorbidityMedical devices presentClinical syndromeAntibioticOutcome

1Hsueh et al., 1996 [2, 6]1 mo/MBurnsVentilatorVentilator-associated pneumoniaCiprofloxacin, cefoxitin, amikacinDied (ARDS)

2Hsueh et al., 1996 [2, 6]5 mo/FNeuroblastoma, chemotherapyHickman catheterBacteremiaNot statedRecovery without removal of catheter (after 3 days)

3Hsueh et al., 1996 [2, 6]1 mo/FHepatoblastoma, chemotherapy Port-A-catheterBacteremiaNot statedRecovery without removal of catheter (after 3 days)

4Cascio et al., 2005 [13] 2 y/MType 1 diabetes mellitusPeripheral catheterBacteremiaCeftriaxone, 10 daysRecovery with removal of catheter (afebrile after 2 days)

5Al-Tatari et al., 2007 [14] 13 y/MCongenital hydrocephalusLumboperitoneal shuntLumboperitoneal shunt infectionTMP-SMX and rifampin (for 14 d after shunt removal) Recovery 24 h after shunt removal

6Bayraktar et al., 2007 [15] 5 mo/MDown syndrome, operation for atrial septal defect and diaphragmatic herniaMechanical ventilationBacteremiaVancomycin and ofloxacinDied

7Douvoyiannis et al., 2010 [16] 33 d/FNoneNoneBacteremiaCefepime, 10 daysRecovery (afebrile after a day)

8Ceylan et al., 2011 [17] 2 mo/MHydrocephaly External shuntMeningitis sepsisAmpicillin sulbactam and levofloxacinDied (cardiopulmonary arrest)

9Calderón et al., 2011 [8]20 d/MCongenital heart diseaseMechanical ventilationVentilator-associated pneumoniaPiperacillin-tazobactam (14 days)Recovery

10Kodama et al., 2013 [18] 3 y/FAcute myeloid leukemia unrelated cord blood stem cell transplantationCentral venous catheterCatheter-related bloodstream infectionCiprofloxacin and minocyclineRecovery with removal of catheter

11Ozcan et al., 2013 [19] 6 mo/MCongenital hydrocephalus, prematurityVentriculoperitoneal shuntMeningitisTMP-SMX and cefoperazone-sulbactam (14 days)Recovery with removal of shunt

12Hendaus et al., 2013 [20] 8 d/FNone NoneMeningitisCefepime (21 days)Recovery (afebrile after 2 days)

13Eshwara et al., 2014 [10]6 d/FSmall for gestational ageNone Meningitis sepsisTMP-SMX (2 weeks) and ciprofloxacin (6 weeks)Recovery

14Olbrich et al., 2014 [21] 11 mo/MHoloprosencephaly, suboptimal hygienic conditionsVentriculoperitoneal shuntMeningitis TMP-SMX and ceftazidime (21 days)Recovery (afebrile in 24 h) with complete removal of the cerebrospinal shunt system

15This study, 20143 mo/FCongenital heart diseaseCentral venous catheterBacteremiaTMP-SMX (21 days)Recovery (afebrile after 2 days)

Chryseobacteria have low pathogenicity and cause infections mostly in hospitalised patients with risk factors including underlying medical illness, age (newborn or elderly) underlying immunocompromising conditions, presence of indwelling intravascular devices, and prolonged exposure to broad-spectrum antibiotics. The present case had congenital heart disease, central venous catheter, and prolonged usage of broad-spectrum antibiotics as risk factors.

The choice of an effective drug for the empirical treatment of infections due to C. indologenes is difficult as the organism has a limited spectrum of antimicrobial sensitivity. Chryseobacterium organisms produce β-lactamases and are resistant to most β-lactam drugs, including the carbapenems and aztreonam [3]. In a study that included 215 C. indologenes isolates, TMP-SMX and cefoperazone-sulbactam remained the most active agent especially for bloodstream infections. Authors concluded that, after introduction of colistin and tigecycline usage because of emerging resistant pathogens, the prevalence of C. indologenes infection increased [12]. According to the results of the SENTRY Antimicrobial Surveillance Program, the most active agents against C. indologenes are the newer quinolones (garenoxacin, gatifloxacin, and levofloxacin, ≥95% susceptibility) and TMP-SMX (95% susceptibility), followed by piperacillin-tazobactam (90% susceptibility). Ciprofloxacin, cefepime, ceftazidime, piperacillin, and rifampin showed reasonable activity (85% susceptibility) [5]. On the contrary, other β-lactams, aminoglycosides, chloramphenicol, linezolid, and glycopeptides are not appropriate for treating infections caused by this organism. According to more recent report it was suggested that only newer fluoroquinolones and TMP-SMX could possibly represent the most appropriate antimicrobial agents [1].

In conclusion C. indologenes may cause nosocomial septicemia in infants with the risk factors as underlying prolonged hospitalization, prolonged usage of broad-spectrum antibiotics, and having comorbidity. The microorganism may have resistance to most antimicrobial agents empirically prescribed for nosocomial Gram-negative infections. For this reason, when C. indologenes is isolated in normally sterile sites of body, antimicrobial susceptibility test results are important to assure appropriate antibiotic coverage. This case report demonstrated that TMP-SMX may be the only appropriate antimicrobial agent to treat bacteremia caused by this pathogen.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.


  1. Y. Lin, Y. Jeng, M. Lin, K. Yu, F. Wang, and C. Liu, “Clinical and microbiological characteristics of Chryseobacterium indologenes bacteremia,” Journal of Microbiology, Immunology and Infection, vol. 43, no. 6, pp. 498–505, 2010. View at: Publisher Site | Google Scholar
  2. P. Hsueh, T. Hsiue, J. Wu et al., “Flavobacterium indologenes bacteremia: clinical and microbiological characteristics,” Clinical Infectious Diseases, vol. 23, no. 3, pp. 550–555, 1996. View at: Publisher Site | Google Scholar
  3. J. P. Steinberg and E. M. Burd, “Other gram-negative and gram-variable bacilli,” in Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, G. L. Mandell, J. E. Bennett, and R. Dolin, Eds., pp. 279–295, Elsevier, Livingstone, Zambia, 7th edition, 2010. View at: Google Scholar
  4. M. J. M. Bonten, F. H. van Tiel, S. van der Geest, H. G. W. Smeets, E. E. Stobberingh, and C. A. Gaillard, “Topical antimicrobial prophylaxis of nosocomial pneumonia in mechanically ventilated patients. Microbiological observations,” Infection, vol. 21, no. 3, pp. 137–139, 1993. View at: Publisher Site | Google Scholar
  5. J. T. Kirby, H. S. Sader, T. R. Walsh, and R. N. Jones, “Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium spp.: report from the SENTRY antimicrobial surveillance program (1997–2001),” Journal of Clinical Microbiology, vol. 42, no. 1, pp. 445–448, 2004. View at: Publisher Site | Google Scholar
  6. P. Hsueh, L. Teng, S. Ho, W. Hsieh, and K. Luh, “Clinical and microbiological characteristics of Flavobacterium indologenes infections associated with indwelling devices,” Journal of Clinical Microbiology, vol. 34, no. 8, pp. 1908–1913, 1996. View at: Google Scholar
  7. G. B. Christakis, S. P. Perlorentzou, I. Chalkiopoulou, A. Athanasiou, and N. J. Legakis, “Chryseobacterium indologenes non-catheter-related bacteremia in a patient with a solid tumor,” Journal of Clinical Microbiology, vol. 43, no. 4, pp. 2021–2023, 2005. View at: Publisher Site | Google Scholar
  8. G. Calderón, E. García, P. Rojas, E. García, M. Rosso, and A. Losada, “Chryseobacterium indologenes infection in a newborn: a case report,” Journal of Medical Case Reports, vol. 5, article 10, 2011. View at: Publisher Site | Google Scholar
  9. B. T. Green and P. E. Nolan, “Cellulitis and bacteraemia due to Chryseobacterium indologenes,” Journal of Infection, vol. 42, no. 3, pp. 219–220, 2001. View at: Publisher Site | Google Scholar
  10. V. K. Eshwara, A. Sasi, F. Munim, J. Purkayastha, L. E. Lewis, and C. Mukhopadhyay, “Neonatal meningitis and sepsis by Chryseobacterium indologenes: a rare and resistant bacterium,” Indian Journal of Pediatrics, vol. 81, no. 6, pp. 611–613, 2014. View at: Publisher Site | Google Scholar
  11. Y. Wang, K. Yeh, S. Chiu et al., “Chryseobacterium indologenes peritonitis in a patient with malignant ascites,” International Medical Case Reports Journal, vol. 4, no. 1, pp. 13–15, 2011. View at: Publisher Site | Google Scholar
  12. F. Chen, G. Wang, S. Teng, T. Ou, F. Yu, and W. Lee, “Clinical and epidemiological features of Chryseobacterium indologenes infections: analysis of 215 cases,” Journal of Microbiology, Immunology and Infection, vol. 46, no. 6, pp. 425–432, 2013. View at: Publisher Site | Google Scholar
  13. A. Cascio, G. Stassi, G. B. Costa et al., “Chryseobacterium indologenes bacteraemia in a diabetic child,” Journal of Medical Microbiology, vol. 54, pp. 677–680, 2005. View at: Google Scholar
  14. H. Al-Tatari, B. I. Asmar, and J. Y. Ang, “Lumboperitonial shunt infection due to Chryseobacterium indologenes,” Pediatric Infectious Disease Journal, vol. 26, no. 7, pp. 657–659, 2007. View at: Publisher Site | Google Scholar
  15. M. R. Bayraktar, E. Aktas, Y. Ersoy, A. Cicek, and R. Durmaz, “Postoperative Chryseobacterium indologenes bloodstream infection caused by contamination of distillate water,” Infection Control and Hospital Epidemiology, vol. 28, no. 3, pp. 368–369, 2007. View at: Publisher Site | Google Scholar
  16. M. Douvoyiannis, S. Kalyoussef, G. Philip, and M. M. Mayers, “Chryseobacterium indologenes bacteremia in an infant,” International Journal of Infectious Diseases, vol. 14, no. 6, pp. e531–e532, 2010. View at: Publisher Site | Google Scholar
  17. A. Ceylan, H. Güdücüoğlu, S. Akbayram, A. Bektaş, and M. Bektaş, “Sepsis caused by Chryseobacterium indologenes in a patient with hydrocephalus,” Mikrobiyoloji Bülteni, vol. 45, pp. 735–740, 2011. View at: Google Scholar
  18. Y. Kodama, M. Nishimura, K. Nakashima et al., “Central intravenous catheter-related bacteremia due to Chryseobacterium indologenes after cord blood transplantation,” Rinsho Ketsueki, vol. 54, pp. 305–310, 2013. View at: Google Scholar
  19. N. Ozcan, T. Dal, and A. Tekin, “Is Chryseobacterium indologenes a shunt-lover bacterium? A case report and review of the literature,” Le Infezioni in Medicina, vol. 21, no. 4, pp. 312–316, 2013. View at: Google Scholar
  20. M. A. Hendaus and K. Zahraldin, “Chryseobacterium indologenes meningitis in a healthy newborn: a case report,” Oman Medical Journal, vol. 28, no. 2, pp. 133–134, 2013. View at: Publisher Site | Google Scholar
  21. P. Olbrich, M. Rivero-Garvía, M. D. Falcón-Neyra et al., “Chryseobacterium indologenes central nervous system infection in infancy: an emergent pathogen?” Infection, vol. 42, no. 1, pp. 179–183, 2014. View at: Publisher Site | Google Scholar

Copyright © 2014 Turkan Aydin Teke et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.